Cumulus Oncology is excited to announce a significant funding milestone, having successfully raised $9 million in a recent financing round. This funding will play a crucial role in furthering our mission to develop innovative anti-cancer therapies, specifically targeting areas of high unmet need within clinical settings. With an unwavering commitment to improving patient outcomes, Cumulus Oncology is poised to enhance treatment options for those battling cancer, an endeavor that is supported by a distinguished team of industry veterans. Our leadership comprises seasoned professionals with extensive backgrounds in oncology drug discovery, pre-clinical and clinical development, and successful commercialization of new treatments. Backed by a well-known entrepreneur in the oncology space, we have the strategic insight and operational expertise necessary to propel our development programs forward. As we progress, we are actively seeking partnerships with organizations that have late-stage discovery and clinical-stage oncology assets. We believe that collaboration will be key to amplifying our impact and accelerating the delivery of life-changing therapies to patients. This funding round not only strengthens our financial foundation but also enhances our ability to innovate within the oncology landscape. The prospect of developing therapies that may transform the standard of care in cancer treatment is at the forefront of our mission, and we are eager to take this next step with the support of our investors and partners.








